More foreign pharma firms, this time Sanofi and GSK, are reorganizing sales and marketing efforts accompanied by layoffs in India. Scrip talks to experts about what’s driving the right-sizing and the wider trend.

While generic drug prices continued to erode in the US during the second quarter of FY23, compliance will be key to the performance of Indian firms such as Torrent and Jubilant through the rest of the year. The US FDA has issued multiple observations in 2022, but an import alert for Glenmark’s Baddi unit is the harshest so far.

While generic drug prices continued to erode in the US during the second quarter of FY23, compliance will be key to the performance of Indian firms such as Torrent and Jubilant through the rest of the year. The US FDA has issued multiple observations in 2022, but an import alert for Glenmark’s Baddi unit is the harshest so far.

A wave of cut-price sitagliptin generics is seen hitting the Indian market with expiry of the patent on Merck’s Januvia, a product that has had a hugely eventful journey over the years including fending off pre-expiry challengers. Will the originator respond with price cuts?